The impact on MIBC and NMIBC as prognostic biomarker superior to clinicopathologic parameters and MKI67, raises FOXM1 to a crucial biomarker for molecular grading and to valuable drug target in bladder cancer (Radhakrishnan and Gartel 2008). Here, MKI67 is linked to urinary bladder carcinoma.